The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft modelKatharine V. Jensen, H. Artee Luchman|PLoS ONE|2017Cited by 68
EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivoKatharine V. Jensen, Samuel Weiss|Neuro-Oncology Advances|2020Cited by 24